Carbapenem Market Size, Share, & Trends Analysis Report By Product Type, By Indication Product Type (Urinary Tract Infections, Bloodstream Infections), By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

Carbapenem market is majorly driven by the rising prevalence of infectious diseases such as urinary tract infections (UTIs), intra-abdominal infections, & bacterial meningitis and the increasing movement of generic product companies. Urinary tract infections (UTIs) are one of the most common infections that lead to emergency or clinic visits or indoor admissions across the world. Carbapenems such as Meropenem-Vaborbactam are approved by FDA for use in such complicated urinary tract infections.

The widespread infections from the community with these organisms are likely to lead to a dramatic increase in empiric carbapenem use. Newer oral carbapenems such as tebipenem have also proven to be effective against the cUTI in clinical trials. Tebipenem also has the added advantage of being effective in lower cUTIs. It also reduces the potential complications and hospitalization costs which gives carbapenems an added advantage over other classes of antibiotics.

Branded products were originally discovered by a company and hold the majority share of the market. There are various branded carbapenems available in the market such as Invanz marketed by Merck & Co, Vabomere by Melinta Therapeutics and Merrem by Pfizer Inc. These carbapenems are effective against a broad spectrum of gram-positive and negative bacteria. Moreover, advantages such as less development of resistance and high tolerability are expected to boost the market of branded products.

Asia Pacific is also anticipated to exhibit strong growth momentum during the forecast period. This growth can be attributed to several factors, such as the growing geriatric population, poor access to healthcare facilities, and dense urbanization. Asia-pacific has a high incidence of community-acquired pneumonia which has become an economic burden in the region. Moreover, firms with generic carbapenem drugs are also expanding their portfolio in the region. Asia Pacific is estimated to own the highest share of the market, due to an improving economic scenario, rising disposable income, and a large patient pool. In February 2022, Sumitomo Dainippon Pharma Co., Ltd partnered with its parent business Sumitomo Dainippon Pharma Co., Ltd to initiate phase 1 research for KSP-1007.

Carbapenem Market Segmentation

Major companies operating in the carbapenem market include the Menarini Group, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Lupin, Kopran Limited, Aurobindo Pharma, Daewoong Pharmaceuticals Co., Ltd., Shenzhen Haibin Pharmaceutical Co. Ltd., and Merck & Co., Inc. In September 2022, GSK plc., and Spero Therapeutics entered into an exclusive licensing agreement for the commercialization of a late-stage antibiotic Tebipenem HBr worldwide except in Japan and some Asian countries. Therefore, initiatives undertaken by key players such as collaboration, agreement, and partnership for the development and commercialization of new carbapenems to treat patient with bacterial infections is projected to fuel the market growth.